Brentuximab vedotin received approval for the treatment of ALCL or other CD30-expressing PTCLs due to its good efficacy based on the ECHELON-2 study; however, patients with ENKTCL were not enrolled (17). The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.